Screening for, Monitoring, and Treatment of Chronic Kidney Disease Stages 1 to 3: A Systematic Review for the U.S. Preventive Services Task Force and for an American College of Physicians Clinical Practice Guideline
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Background: Screening and monitoring for chronic kidney disease (CKD) could lead to earlier interventions that improve clinical outcomes. Purpose: To summarize evidence about the benefits and harms of screening for and monitoring and treatment of CKD stages 1 to 3 in adults. Data Sources: MEDLINE (1985 through November 2011), reference lists, and expert suggestions. Study Selection: English-language, randomized, controlled trials that evaluated screening for or monitoring or treatment of CKD and that reported clinical outcomes. Data Extraction: Two reviewers assessed study characteristics and rated quality and strength of evidence. Data Synthesis: No trials evaluated screening or monitoring, and 110 evaluated treatments. Angiotensin-converting enzyme inhibitors (relative risk, 0.65 [95% CI, 0.49 to 0.88]) and angiotensin II–receptor blockers (relative risk, 0.77 [CI, 0.66 to 0.90]) reduced end-stage renal disease versus placebo, primarily in patients with diabetes who have macroalbuminuria. Angiotensin-converting enzyme inhibitors reduced mortality versus placebo (relative risk, 0.79 [CI, 0.66 to 0.96]) in patients with microalbuminuria and cardiovascular disease or high-risk diabetes. Statins and β-blockers reduced mortality and cardiovascular events versus placebo or control in patients with impaired estimated glomerular filtration rate and either hyperlipidemia or congestive heart failure, respectively. Risks for mortality, end-stage renal disease, or other clinical outcomes did not significantly differ between strict and usual blood pressure control. The strength of evidence was rated high for angiotensin II–receptor blockers and statins, moderate for angiotensin-converting enzyme inhibitors and β-blockers, and low for strict blood pressure control. Limitations: Evidence about outcomes was sometimes scant and derived from post hoc analyses of subgroups of patients enrolled in trials. Few trials reported or systematically collected information about adverse events. Selective reporting and publication bias were possible. Conclusion: The role of CKD screening or monitoring in improving clinical outcomes is uncertain. Evidence for CKD treatment benefit is strongest for angiotensin-converting enzyme inhibitors and angiotensin II–receptor blockers, and in patients with albuminuria combined with diabetes or cardiovascular disease. Primary Funding Source: Agency for Healthcare Research and Quality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
Parving, H.-H., Lehnert, H., Bröchner-Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011489 · Cited by 2,873
Gerstein, H. C. (2001) · JAMA · doi:10.1001/jama.286.4.421 · Cited by 2,440
Research works printed but not linked: 67
- National Kidney Foundation, 2002, Am J Kidney Dis, 39, S1
- 10.1038/ki.2010.550 · DOI · Paper page
- 10.1136/bmj.327.7414.557 · DOI · Paper page
- 10.1016/S0011-393X(99)90003-6 · DOI
- 10.1016/S0168-8227(01)00289-3 · DOI
- 10.7326/0003-4819-118-8-199304150-00001 · DOI · Paper page
- 10.2337/diacare.24.5.919 · DOI · Paper page
- 10.2337/diacare.21.1.104 · DOI · Paper page
- 10.1136/bmj.37970.629537.0D · DOI · Paper page
- 10.1016/S0002-9343(99)80226-5 · DOI · Paper page
- 10.2337/diacare.23.12.1823 · DOI · Paper page
- 10.1681/ASN.2007020256 · DOI
- 10.1161/01.CIR.0000146378.65439.7A · DOI · Paper page
- 10.1016/S0140-6736(96)11445-8 · DOI · Paper page
- 10.1056/NEJM199604113341502 · DOI · Paper page
- 10.1016/0895-7061(95)00162-I · DOI · Paper page
- 10.1016/j.jacc.2007.08.029 · DOI
- 10.1161/CIRCULATIONAHA.105.592733 · DOI · Paper page
- 10.7326/0003-4819-134-8-200104170-00007 · DOI · Paper page
- Strippoli GF, 2006, Cochrane Database Syst Rev, CD006257
- 10.2337/diacare.17.5.420 · DOI · Paper page
- 10.1161/CIRCULATIONAHA.110.964171 · DOI · Paper page
- 10.1016/S0140-6736(08)61236-2 · DOI · Paper page
- 10.1097/HJH.0b013e32830508aa · DOI · Paper page
- 10.1016/j.diabres.2005.06.010 · DOI
- 10.1046/j.1523-1755.2000.00224.x · DOI · Paper page
- 10.1681/ASN.2006121372 · DOI · Paper page
- 10.1161/CIRCULATIONAHA.109.853648 · DOI · Paper page
- 10.2215/CJN.01110905 · DOI
- 10.1016/j.cardfail.2008.11.003 · DOI
- 10.1093/eurjhf/hfp104 · DOI · Paper page
- 10.1161/CIRCHEARTFAILURE.109.932558 · DOI
- 10.1093/eurjhf/hfq038 · DOI
- 10.1001/archinte.158.12.1340 · DOI
- 10.1001/jama.288.19.2421 · DOI · Paper page
- 10.1038/ki.1995.361 · DOI · Paper page
- 10.1161/01.HYP.13.5_Suppl.I80 · DOI · Paper page
- 10.1016/S0140-6736(05)71082-5 · DOI · Paper page
- 10.1046/j.1523-1755.2002.00213.x · DOI · Paper page
- 10.1016/S0272-6386(99)70036-3 · DOI · Paper page
- 10.1056/NEJMoa0910975 · DOI · Paper page
- Ridker PM, 2010, J Am Coll Cardiol, 55, 1266, 10.1016/j.jacc.2010.01.020 · DOI · Paper page
- 10.1016/j.amjcard.2004.10.008 · DOI
- 10.1053/j.ajkd.2009.09.020 · DOI · Paper page
- 10.1016/j.atherosclerosis.2010.07.053 · DOI
- 10.1016/j.atherosclerosis.2009.03.031 · DOI
- 10.1053/j.ajkd.2008.05.027 · DOI
- 10.1161/01.CIR.0000143892.84582.60 · DOI · Paper page
- 10.1007/s00125-009-1467-8 · DOI · Paper page
- 10.1053/j.jrn.2005.07.003 · DOI · Paper page
- D'Amico G, 1994, Nephrol Dial Transplant, 9, 1590
- 10.1016/0140-6736(91)92977-A · DOI · Paper page
- Rosman JB, 1989, Kidney Int Suppl, 27, S96
- 10.1136/bmj.311.7011.973 · DOI · Paper page
- 10.2337/dc08-1908 · DOI · Paper page
- 10.1093/qjmed/hch039 · DOI
- 10.1016/S0002-9343(98)00329-5 · DOI
- 10.2215/CJN.07160810 · DOI
- 10.1016/j.amjmed.2007.05.012 · doi:10.1016/j.amjmed.2007.05.012
- 10.1053/ajkd.2003.50007 · DOI · Paper page
- 10.1056/NEJMoa021835 · DOI · Paper page
- 10.1053/j.ajkd.2009.11.017 · DOI
- 10.1001/jama.290.23.3101 · DOI · Paper page
- 10.1038/sj.ki.5001794 · DOI · Paper page
- 10.1097/01.ASN.0000091586.46532.B4 · DOI · Paper page
- 10.1038/sj.ki.5000058 · DOI · Paper page
- 10.1681/ASN.2010091001 · DOI · Paper page
Cited by
Romagnani, P., Remuzzi, G., Glassock, R., Levin, A., Jager, K. J., Tonelli, M., Massy, Z., Wanner, C., & Anders, H.-J. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.88 · Cited by 996
May, C. R., Cummings, A., Girling, M., Bracher, M., Mair, F. S., May, C. M., Murray, E., Myall, M., Rapley, T., & Finch, T. (2018) · Implementation Science · doi:10.1186/s13012-018-0758-1 · Cited by 683
Ene-Iordache, B., Perico, N., Bikbov, B., Carminati, S., Remuzzi, A., Perna, A., Islam, N., Bravo, R. F., Aleckovic-Halilovic, M., Zou, H., et al. (2016) · The Lancet Global Health · doi:10.1016/s2214-109x(16)00071-1 · Cited by 627
Reducing the costs of chronic kidney disease while delivering quality health care: a call to action
on behalf of the European Kidney Health Alliance, Vanholder, R., Annemans, L., Brown, E., Gansevoort, R., Gout-Zwart, J. J., Lameire, N., Morton, R. L., Oberbauer, R., Postma, M. J., et al. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.63 · Cited by 368
Lucas, G. M., Ross, M. J., Stock, P. G., Shlipak, M. G., Wyatt, C. M., Gupta, S. K., Atta, M. G., Wools-Kaloustian, K. K., Pham, P. A., Bruggeman, L. A., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu617 · Cited by 310
Metadata
- Authors
- Fink, H. A., Ishani, A., Taylor, B. C., Greer, N. L., MacDonald, R., Rossini, D., Sadiq, S., Lankireddy, S., Kane, R. L., & Wilt, T. J.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2012-04-17
- Volume
- 156
- Issue
- 8
- Pages
- 570-581
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W4238687915
- Cited by
- 154
- References
- 25
- FWCI
- 2.47
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Screening for, Monitoring, and Treatment of Chronic Kidney Disease Stages 1 to 3: A Systematic Review for the U.S. Preventive Services Task Force and for an American College of Physicians Clinical Practice Guideline. https://app.cochat.ai/papers/10.7326/0003-4819-156-8-201204170-00008
- The paper
- Fink, H. A., Ishani, A., Taylor, B. C., Greer, N. L., MacDonald, R., Rossini, D., Sadiq, S., Lankireddy, S., Kane, R. L., & Wilt, T. J. (2012). Screening for, Monitoring, and Treatment of Chronic Kidney Disease Stages 1 to 3: A Systematic Review for the U.S. Preventive Services Task Force and for an American College of Physicians Clinical Practice Guideline. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-156-8-201204170-00008
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.